Arbutus Biopharma (ABUS) Reports In-Line Q3 EPS; Cash and Cash Equivalents of 151.9M
Arbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $3.34 million versus the consensus estimate of $2.38 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.